Cartagenia, a Leuven, Belgium-based provider of knowledge, software and services for efficient patient genetics, has raised €2.2m in funding.
Investors include existing shareholders PMV/VINNOF and Gemma Frisius Fund and the founders, which all together injected €1.1m, and Euronext-listed Quest for Growth, which committed the other half of the capital.
The company, which was spun out of K.U. Leuven in 2008, intends to use the funds to further develop its market presence, to start up an office in the United States and to invest in a new product line.
Led by CEO Herman Verrelst and Operations Director Bert Coessens Ph.D, Cartagenia delivers diagnostic knowledge, software and database systems, and related services to enable genetic labs and clinicians to perform clinically relevant genetic analyses efficiently, and allow them to offer patients and carers high quality genetic interpretation and counseling.